There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .
Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates.
OBJECTIVE We tested the hypothesis of whether a pharmacologic , orogastric dose of docosahexaenoic acid ( DHA ) administered during the acute phase of sepsis protects the nutritional status of neonates . METHODS A r and omized , placebo-controlled trial was conducted . Neonates who developed sepsis after a surgical procedure were r and omly assigned to receive daily 100 mg of DHA or 100 mg of olive oil as placebo for 14 d. At selection , illness severity was evaluated and a blood sample was obtained to measure erythrocyte fatty acid composition . Energy intake and type of feeding were recorded daily . Body composition was also determined at selection and after 14 d of follow-up with the deuterium dilution technique . Body composition differences between d 14 and baseline were calculated and compared between groups . Confounders were analyzed in a multiple regression model . RESULTS In all , 16 DHA and 11 placebo cases were followed up . Both groups showed an increase in length and head circumference , but length gain tended to be greater in neonates with DHA ( P = 0.07 ) . The DHA group presented increases in body mass ( 50 g , P = 0.03 ) and fat mass ( 70 g , P = 0.03 ) , whereas infants in the placebo group did not show an increase in any body composition components . Gain in fat mass was positively related with the DHA of erythrocytes and whether or not infants received DHA . CONCLUSIONS Orogastric DHA administered in the acute phase of infection likely protects the nutritional status of neonates with sepsis
There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .